Meeker David P's Form 4 filing
Rhythm Pharmaceuticals, Inc. (RYTM) · filed Feb 19, 2025
- Accession no.
- 0001104659-25-015322
- Filed
- Feb 19, 2025
- Trade date
- Feb 14-19, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $566.2K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meeker David PCIK 0001385155 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2025 | Common Stock | MOption exerciseAcquired | +21,250 | – | – | 211,177 | Direct | |
| Feb 19, 2025 | Common Stock | SSaleDisposed | −9,896 | $57.22 | −$566,249.12 | 201,281 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | Common Stock | AGrant or awardAcquired | +133,350 | $0.00 | $0 | 133,350 | Direct | |
| Feb 14, 2025 | Common Stock | AGrant or awardAcquired | +200,000 | $0.00 | $0 | 200,000 | Direct | |
| Feb 16, 2025 | Common Stock | MOption exerciseDisposed | −21,250 | $0.00 | $0 | 63,750 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.